GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
The conversation is about someone looking for specific side effects reported in clinical trials for GT20029, a hair loss treatment. No results or data were found on the clinical trials site.
The post and conversation are about the high cost and skepticism surrounding pyrilutamide as a hair loss treatment, with comparisons to minoxidil, finasteride, and RU58841. The original poster defends pyrilutamide's effectiveness and criticizes others for dismissing it without proper understanding.
Adding tretinoin to a minoxidil routine can cause initial hair shedding, which may be normal as it potentially increases minoxidil's efficacy. Users suggest being cautious with tretinoin application, especially around microneedling, to avoid increased systemic absorption.
The conversation discusses using a low dose of topical finasteride to achieve hair benefits with minimal systemic exposure. Users share experiences and opinions on dosing, systemic buildup, and side effects of both topical and oral finasteride.
A user is considering switching from oral to topical finasteride to reduce systemic DHT impact and is exploring ethossomal finasteride for better skin penetration and potential hair regrowth. They found ethossomal finasteride in Brazil and are seeking opinions on its effectiveness compared to other topical delivery methods.
The conversation discusses the effectiveness and safety of hair loss treatments, specifically RU58841 and Pyrilutimide (Pyril), with users sharing that Pyril was no more effective than a placebo and expressing concerns about the safety of RU58841 based on personal experiences and the lack of pharmaceutical interest.
The conversation discusses using homemade topical finasteride for hair loss, showing an increase in DHT levels despite treatment. The user applies 0.125mg daily, resulting in 113.4% of previous DHT levels.
Hair loss treatment progress with Dut, Min, Keto, needling, and RU/Min/Fin/Dut topical. User noticed improvement, believes RU and needling most effective.
A user shared their successful hair regrowth using a combination of derma stamping, Retinol, Minoxidil, Dutasteride, and RU58841, with no side effects. Others discussed their varied experiences with these treatments, including concerns about potential side effects like heart issues and sexual dysfunction.
The conversation discusses hair loss treatments using oral minoxidil, oral dutasteride, and mesotherapy dutasteride, showing impressive 6-month results. The user wishes these treatments were available in the U.S.
A user shared their experience using topical finasteride for 6 months, showing a reduction in DHT levels but no visible improvement in hair loss. They are considering switching to oral finasteride for potentially better results.
Minoxidil may age skin by slowing collagen synthesis, but using collagen peptides and a basic skincare routine might counteract this. Foam minoxidil could reduce systemic absorption and avoid alcohol-related side effects.
Oral minoxidil may be more effective than topical due to uniform distribution and systemic activation, but can cause side effects like puffiness. Adding tretinoin to topical minoxidil can enhance its effectiveness by aiding conversion to its active form.
Diet can influence hair health, but male pattern baldness (MPB) is primarily genetic. Treatments discussed include Minoxidil, finasteride, and RU58841.
The conversation discusses avoiding caffeine after Platelet-Rich Plasma (PRP) treatment for hair loss because caffeine is a vasoconstrictor, which can reduce blood flow and hinder the healing process that PRP aims to promote.
The user is using 0.1% dutasteride, 1% minoxidil with 2% procapil and 0.005% caffeine in the morning, and 1% minoxidil with 2% procapil and 0.01% tretinoin at night. They are concerned about the solution vehicle's effectiveness in preventing systemic absorption and ensuring the products stay around the hair follicles.
Efforts to find a Canadian dermatologist in the US to prescribe H&W's topical finasteride for hair loss. The user is willing to fund a crowd-share effort to identify prospects.
A user applied a homemade topical finasteride solution daily for 35 days, reducing hair shedding significantly with minimal side effects. They plan to continue for 90 days and will provide further updates.
A user discusses using topical dutasteride 0.025% once a week for hair maintenance, alongside fortified minoxidil, RU58841, and Reviv Hair Serum. They seek feedback on the effectiveness of this regimen.
The safety and effectiveness of RU-58841 as a hair loss treatment, with some users reporting side effects like chest pains, while others had positive results. The original research on RU-58841 was likely stopped due to financial issues, not safety concerns.
The user plans to dermaroll and use minoxidil for hair loss over the next 4 months, documenting progress monthly. They will also consider finasteride later and include vitamins, a custom shampoo, castor oil, scalp massages, and increased water intake in their regimen.
TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.
Comparing the effectiveness and side effects of topical finasteride versus oral finasteride, with people sharing their experiences using both treatments to manage hair loss.
The user experienced significant hair shedding in the second week of using pyrilutamide, more so than with finasteride and minoxidil, and reported a headache after the first application. They believe the treatment may be working but acknowledge it's too early to confirm results.
The potential of using a specific antibody, HMI-115, as a treatment for hair loss alongside traditional treatments such as minoxidil and finasteride. The user suggests trying either a 240 mg or 30 mg dose to see if it works.
The conversation discusses arranging an interview with the developers of RU58841 to clarify its safety and reasons for halted research, with some users expressing concerns about potential risks and others citing financial reasons for the discontinuation of studies. Specific treatments mentioned include RU58841, minoxidil, and finasteride.